TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36263035
Drug: Slow-paced breathing
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-paced breathing (4sec inhalation, 6sec exhalation for 20 minutes 3x daily)
Study: 36263035
Drug: Slow-paced breathing
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-paced breathing (dose-response relationship)
Study: 32131866
Drug: IC43 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: IC43 100 μg
Study: 39499492
Drug: pembrolizumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: pembrolizumab + chemotherapy
Study: 35855386
Drug: Citrus aurantium
Normalized name: Citrus aurantium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrus aurantium essential oil (5 drops, twice a day for one month)
Study: 35855386
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice a day for one month)
Study: 33954198
Drug: PECS II
Approvals — FDA: no, EMA: no, PMDA: no
Description: PECS II (0.5% ropivacaine 25 ml)
Study: 35616436
Drug: Naltrexone and
Normalized name: Naltrexone and Bupropion Hydrochlorides Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone and acamprosate (alone and in combination)
Study: 32785710
Drug: Methylprednisolone (MP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MP) 0.5 mg/kg intravenously twice daily for 5 days
Study: 32188386
Drug: Established markers
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Established markers of inflammation (e.g., C-reactive protein)
Study: 32188386
Drug: Newer inflammatory
Normalized name: Arthriten Inflammatory Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer inflammatory markers (e.g., lipoprotein-associated phospholipase A2, cytokines, myeloperoxidase)
Study: 32188386
Drug: Anti-inflammatory and
Normalized name: MENTHOL 20 mg in 1 mL TOPICAL CREAM [Phoenix KinetiCream Anti-inflammatory and Pain Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory and pleiotropic drugs
Study: 32438719
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of grapefruit, bitter orange, and olive extracts for eight weeks
Study: 35894768
Drug: Routine hypoglycemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine hypoglycemic drugs + resistance training (AE + RT)
Study: 35894768
Drug: Routine hypoglycemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine hypoglycemic drugs
Study: 33499570
Drug: Pulsed Dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Dye Laser (PDL) treatment every 1 week
Study: 33499570
Drug: Pulsed Dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Dye Laser (PDL) treatment every 2 weeks
Study: 33499570
Drug: Pulsed Dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Dye Laser (PDL) treatment every 3 weeks
Study: 33499570
Drug: Pulsed Dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Dye Laser (PDL) treatment every 4 weeks
Study: 34284099
Drug: Tamoxifen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen treatment in poor CYP2D6 metabolizers
Study: 34284099
Drug: Tamoxifen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen treatment in intermediate CYP2D6 metabolizers
Study: 34284099
Drug: Tamoxifen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen treatment in normal CYP2D6 metabolizers
Study: 34284099
Drug: Tamoxifen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen treatment in ultrarapid CYP2D6 metabolizers
Study: 35162842
Drug: Submucosal intralesional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submucosal intralesional injections of dexamethasone (2 mL; 4 gm/mL)
Study: 34541864
Drug: TARE plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TARE plus chemotherapy
Study: 34924512
Drug: Cognitive-Behavioral-Based Physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral-Based Physical Therapy (CBPT-Trauma)
Study: 32631130
Drug: Mobile interventionist
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile interventionist approach as an add-on to assertive community treatment (ACT)
Study: 32631130
Drug: Assertive community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assertive community treatment (ACT) alone
Study: 33965364
Drug: Online weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online weight management platform with weekly coaching calls (weeks 1–12) tapered to bi-weekly calls (weeks 12–24)
Study: 32907547
Drug: BELIEF protocol
Normalized name: Ora Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: BELIEF protocol (two face-to-face counseling sessions at 24 and 34 weeks of pregnancy, plus eight weekly telephone counseling sessions)
Study: 33981369
Drug: Probiotic supplement
Normalized name: Align Probiotic Supplement Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplement preparation (PSP)
Study: 36152764
Drug: 25% IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% IV albumin 1.5 g/kg weekly infusions
Study: 34484562
Drug: Anthocyanin-rich mulberry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthocyanin-rich mulberry milk (2 servings daily)
Study: 34484562
Drug: Anthocyanin-rich mulberry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthocyanin-rich mulberry milk (1 serving daily)
Study: 32673160
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise training at 65-85% V̇o2peak for 24 weeks, prescribed dose of 8 kcal·kg body wt‐1·wk‐1 (8 KKW) or 20 KKW
Study: 37001859
Drug: Cemiplimab plus
Normalized name: cemiplimab
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab plus chemotherapy (350 mg every 3 weeks for up to 108 weeks)
Study: 38820979
Drug: Cemiplimab plus
Normalized name: cemiplimab
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab plus chemotherapy
Study: 33550716
Drug: Cold atmospheric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold atmospheric plasma (CAP) pretreatment before topical anesthetic cream application
Study: 33550716
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic cream only (control)
Study: 33389549
Drug: Clazosentan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazosentan (20 mg/h followed by 60 mg/h continuous infusion)
Study: 33389549
Drug: Clazosentan (simulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazosentan (simulated 15 mg/h for 3 hours)
Study: 33149899
Drug: Various therapeutic
Normalized name: Various therapeutic radiopharmaceuticals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various therapeutic agents tested in adaptive platform trials
Study: 33259247
Drug: Concurrent training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent training (CT) (n=14)
Study: 35255929
Drug: Mesenchymal stromal
Normalized name: Mesenchymal Stromal Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stromal cells (MSCs) plus basiliximab and calcineurin inhibitor
Study: 33899447
Drug: Complex spa
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex spa treatment with transcranial magnetic therapy (TCMT)
Study: 33899447
Drug: Identical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical treatment complex without TCMT (Control)
Study: 33899447
Drug: Complex spa
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex spa treatment with TCMT
Study: 34033812
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg daily until delivery
Study: 33321501
Drug: Guided internet-
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided internet- and mobile-based intervention (IMI) tailored to CBP plus treatment-as-usual (TAU)
Study: 33136049
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received only standard IANB injection of 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
Study: 32295442
Drug: Integrative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative treatment (Western medicine combined with Jianpi Huatan Tongfu granule)
Study: 32295442
Drug: Western medical
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medical treatment
Study: 34018381
Drug: Inhalation aromatherapy
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation aromatherapy with Rosa damascena (5 drops of 40% for 20 minutes)
Study: 34018381
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (inhalation of distilled water)
Study: 34018381
Drug: Inhalation aromatherapy
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation aromatherapy with Rosa damascena
Study: 35358592
Drug: Bevacizumab (subconjunctival
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (subconjunctival 2.5 mg/0.1 ml at surgery and topical 10 mg/ml 4 times per day for 4 weeks)
Study: 34229619
Drug: Telephone therapist
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone therapist delivered cognitive behavioural therapy (TCBT)
Study: 34229619
Drug: Web-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based cognitive behavioural therapy (WCBT)
Study: 32166564
Drug: T3-L-CGMs (50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: T3-L-CGMs (50% level of T1)
Study: 34453878
Drug: Group-based treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based treatments
Study: 32092060
Drug: ALVAC-HIV (vCP2438)
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines
Study: 32298501
Drug: 100% insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% insulin dose
Study: 32298501
Drug: 130% insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 130% insulin dose
Study: 32298501
Drug: 145% insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 145% insulin dose
Study: 32298501
Drug: 160% insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160% insulin dose
Study: 33575961
Drug: Thymus thymalin
Normalized name: THYMUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymus thymalin (peptide drug)
Study: 34085478
Drug: Penetrating moxibustion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penetrating moxibustion at governor vessel, 2 h per treatment, once a week for 4 weeks
Study: 34085478
Drug: Momethasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Momethasone furoate nasal spray, 2 sprays per side per time, once a day for 4 weeks
Study: 32141112
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBMT) - 12 sessions of 20 minutes each, energy/session 4.08 J/cm2, thrice/week
Study: 32141112
Drug: Non-contact selective-field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-contact selective-field radiofrequency (NcRF) - four 30-minute treatments once/week
Study: 34210681
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg Q3W plus ipilimumab 50 mg Q6W for 4 doses (PEM200+IPI50)
Study: 34210681
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg Q3W plus ipilimumab 100 mg Q12W for 4 doses (PEM200+IPI100)
Study: 35129010
Drug: Gluteal trigger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluteal trigger point injection (TP)
Study: 35415804
Drug: Enhanced arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced arm (didactic plus weekly messaging and monetary inducement)
Study: 34934054
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg kg-1) acute
Study: 33524917
Drug: Radically open
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radically open dialectical behavior therapy (RO DBT)
Study: 39028879
Drug: Dual antithrombotic
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antithrombotic therapy (DAT)
Study: 35137493
Drug: Intranasal naloxone
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal naloxone (1.4 mg/0.1 mL)
Study: 35137493
Drug: Intramuscular naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular naloxone (0.8 mg/2 mL)
Study: 33257495
Drug: Concurrent Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Treatment of PTSD and Substance Use Using Prolonged Exposure - Adolescent (COPE-A)
Study: 35123427
Drug: Next pharmacological
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Next pharmacological step (switch to tricyclic antidepressant or augmentation with lithium or second-generation antipsychotic) combined with CBT
Study: 32481305
Drug: Shenfu Qiangxin
Normalized name: Dianexin
DrugBank: Dianexin (DB15000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu Qiangxin Pills (SFQX)
Study: 35546412
Drug: Customized app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Customized app with individual feedback regarding self-reported medication intake for 12 months
Study: 35546412
Drug: Customized app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Customized app without individual feedback regarding self-reported medication intake for 12 months
Study: 33026243
Drug: Ertugliflozin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin (5 mg, 15 mg pooled)
Study: 32577113
Drug: Automated daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated daily text-messages regarding pain, opioid utilization, and a daily CBT intervention
Study: 35718313
Drug: Healthy comfort
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy comfort food (e.g., grapes)
Study: 35718313
Drug: Unhealthy comfort
Normalized name: Comfort Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unhealthy comfort food (e.g., chips)
Study: 33276744
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (45 min once a week for 12 weeks)
Study: 34035312
Drug: Fluticasone furoate/umeclidinium/vilanterol
Normalized name: Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 mcg via ELLIPTA
Study: 34035312
Drug: Tiotropium (TIO)
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (TIO) 18 mcg via HandiHaler
Study: 35124187
Drug: Investigators' practices
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigators' practices following trial discontinuation
Study: 34060027
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NACT) followed by cold knife conization (CKC)
Study: 35745176
Drug: Test potato
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test potato cv. SQ containing 45 mg anthocyanin
Study: 34116176
Drug: Ciprofol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofol 0.5 mg/kg
Study: 34619937
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of community-based comprehensive intervention and internet-based intervention (Group B)
Study: 34048716
Drug: 4 weeks
Normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks of amoxicillin‐clavulanate (25‐35 mg/kg twice daily oral suspension)
Study: 34048716
Drug: 2 weeks
Normalized name: Rykindo, 25 mg/2 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 weeks of amoxicillin‐clavulanate followed by 2 weeks of placebo
Study: 34048716
Drug: 4 weeks
Normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks of amoxicillin‐clavulanate
Study: 35460434
Drug: 4 weeks’
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks’ daily remote ischaemic conditioning (CRIC)
Study: 38184633
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (control group).
Study: 36167307
Drug: G-CSF (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (starting at day +3 post Auto-HSCT)
Study: 36167307
Drug: No G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No G-CSF (G-CSF withheld after Auto-HSCT)
Study: 36167307
Drug: G-CSF and
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF and No G-CSF
Study: 33726828
Drug: Low-dose theophylline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose theophylline (200 mg ER, Unicontin-E) once daily for 52 weeks
Study: 33726828
Drug: Low-dose theophylline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose theophylline (200 mg ER, Unicontin-E)
Study: 36857968
Drug: Dasatinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib (100 mg/d) and Quercetin (1250 mg/d), three consecutive days per week for three weeks
Study: 34709013
Drug: Adductor canal
Normalized name: Canalevia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adductor canal block with 20 mL of ropivacaine 0.5%
Study: 32734847
Drug: Inoculated with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inoculated with 20 μl of spore suspension (10^4 conidia per ml) from a 21-day-old PDA culture.
Study: 36257876
Drug: Bursitis label
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bursitis label plus treatment recommendation
Study: 36257876
Drug: Rotator cuff
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotator cuff tear label plus treatment recommendation
Study: 36257876
Drug: Treatment recommendation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment recommendation
Study: 34409858
Drug: Balstilimab in
Normalized name: Balstilimab
DrugBank: Balstilimab (DB15676)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balstilimab in combination with zalifrelimab
Study: 33232912
Drug: Krill oil
Normalized name: Krill oil
DrugBank: Krill oil (DB16615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krill oil supplementation (400 mg EPA and DHA for 3 months, then 800 mg EPA and DHA for 9 months)
Study: 36349244
Drug: E-OJ-01 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: E-OJ-01 (400 mg/day for 8 weeks)
Study: 32903142
Drug: Same-day administration
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same-day administration of pegfilgrastim
Study: 35040594
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily nasal irrigation with Johnson and Johnson's Baby Shampoo (J&J) in hypertonic saline
Study: 35687807
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) components (problem solving, changing unhelpful thoughts, relaxation skills)
Study: 35687807
Drug: Barriers (being
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barriers (being bullied, difficulty applying therapy content to new situations)
Study: 33755143
Drug: linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin 5 mg daily for 48 weeks
Study: 32692386
Drug: Levothyroxine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine treatment (25 µg titrated to aim for serum thyrotropin levels between 0.4 and 2.5 mU/L)
Study: 32873953
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (NaHCO3, 1.68 g)
Study: 34916444
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg Lycium barbarum polysaccharide (LBP) for 6 weeks
Study: 32165040
Drug: Chemotherapy at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy at Ben Taub Hospital (BTH)
Study: 32799841
Drug: Peripheral intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral intravenous parenteral nutrition (P-PN)
Study: 35738551
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + a-PDT (methylene blue mediated antimicrobial photodynamic therapy using 660 nm diode laser)
Study: 35791455
Drug: Dexmedetomidine 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 5.0 mcg
Study: 35791455
Drug: Dexmedetomidine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 7.5 mcg
Study: 35791455
Drug: Dexmedetomidine 10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 10.0 mcg
Study: 33151775
Drug: Intravenous ascorbate
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ascorbate (VitC) 2g
Study: 35127522
Drug: High OC/OL‐EVOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: High OC/OL‐EVOO (40 ml/day, 416 mg/Kg OC and 284 mg/kg OL for 3 months)
Study: 35127522
Drug: High OC/OL‐EVOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: High OC/OL‐EVOO (40 ml/day for 6 months)
Study: 35127522
Drug: Low OC/OL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low OC/OL (40 ml/day, 82 mg/kg OC and 33 mg/kg OL for 3 months)